This website has been commissioned by Ipsen Pharmaceuticals Ltd. and is intended for an Irish audience. If you are not a Healthcare Professional, please click here.
Adverse event reporting information is available at the bottom of this webpage.

Decapeptyl® (triptorelin) and your treatment journey guide

Prostate Cancer File
12 pages

This guide is intended only for men prescribed LHRHa treatment for prostate cancer with Decapeptyl® (triptorelin). It is designed to help men understand their prostate cancer treatment and how to get the most from it.

TRI-IE-000608 | August 2025

Decapeptyl<sup>®</sup> (triptorelin) and your treatment journey guide
Explore more Prostate Cancer Resources

Explore more Prostate Cancer Resources

Browse

To access relevant information about Prostate Cancer, please choose one of the following options:

Adverse events should be reported.
Reporting forms and information can be found at www.hpra.ie or e-mail medsafety@hpra.ie.
The HPRA can also be contacted on +353 16764971. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256.

Reporting of side effects:
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly to the HPRA. Reporting forms and information can be found at www.hpra.ie or email medsafety@hpra.ie. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256. By reporting side effects, you can help provide more information on the safety of this medicine.